Welcome

The 2017 AACI/CCAF Annual Meeting convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies. The three-day event aims to develop solutions to common challenges and to share best practices.

This year, AACI is excited to welcome 25 new cancer center directors to its ranks. This unprecedented leadership turnover promises fresh perspectives on the association’s mission to assist centers in keeping pace with the changing landscape in science, technology and health care. We look forward to the dedicated service of this new wave of cancer center leaders as we work together to improve the prevention, detection and treatment of cancer.

We are also very pleased to welcome National Cancer Institute acting director Doug Lowy, MD, and incoming director Norman “Ned” Sharpless, MD, who recently led the University of North Carolina Lineberger Comprehensive Cancer Center and was a member of the AACI Board of Directors.

This year’s annual meeting program, jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF), includes an opening keynote presentation by Stan Collender, a federal budget issues expert and Merkel cell carcinoma survivor, and a talk by Carl H. June, MD, the 2017 AACI Distinguished Scientist Awardee.

The program also features an update on AACI’s Network Care Initiative, which is led by AACI President Stanton L. Gerson, MD, followed by a panel discussion on managing cancer center networks. Other presentations will focus on immunotherapy, clinical trials, precision medicine, cancer disparities, and the impact of Washington’s new political landscape on financing cancer care.

No other event provides information on cancer research and patient care issues as they pertain to academic cancer center leaders, and provides them with a forum to discuss common issues. On behalf of the 2017 AACI/CCAF Annual Meeting Program Committee, welcome to the nation’s capital!
Program Committee

Chair: Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center at Thomas Jefferson University

Gerold Bepler, MD, PhD
Barbara Ann Karmanos Cancer Institute
Wayne State University

Maryann Donovan, PhD, MPH
UPMC Hillman Cancer Center

Stanton L. Gerson, MD
Case Comprehensive Cancer Center

Laurie H. Glimcher, MD
Dana-Farber Cancer Institute
Harvard Medical School

David M. Gosky, MA, MBA
UK Markey Cancer Center

Roy A. Jensen, MD
The University of Kansas Cancer Center

Eduardo Sotomayor, MD
GW Cancer Center

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Jane Welter, MBA
Mayo Clinic Cancer Center

Cheryl L. Willman, MD
University of New Mexico
Comprehensive Cancer Center

Alex Zafirovski, MBA, RTT ARRT
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Agenda

All sessions will be held in the Independence Ballroom A, Independence Level, except where indicated.

Sunday, October 15

11:00 am  Meeting Registration Begins
Independence Foyer, Independence Level

11:00 am  Exhibits Open
Independence Foyer, Independence Level

1:00 pm  Welcome and AACI Business Meeting

President’s Report
Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Executive Director’s Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer’s Report
Mr. Randall C. Main
Fred Hutchinson Cancer Research Center

Program Chair’s Report
Dr. Karen E. Knudsen
Sidney Kimmel Cancer Center at Thomas Jefferson University

CCAF Report
Mr. David M. Gosky
UK Markey Cancer Center

1:45 pm  Opening Keynote Speaker

Mr. Collender will focus his talk on the President’s proposed budget cuts to biomedical research and the impact a cut would have on academic cancer centers and their ability to care for patients. This topic will be addressed from Mr. Collender’s unique perspective as both a federal budget expert and a cancer survivor.

Mr. Stan Collender
MSLGROUP

2:45 pm  Break

All 2017 AACI/CCAF Annual Meeting sessions will be held in the Independence Ballroom A, Independence Level, except where indicated.
Sunday, October 15

3:00 pm  **Impact of the New CCSG Guidelines on the Cancer Centers**
This panel discussion will explore the practical ramifications of recently revised guidelines for NCI’s Cancer Center Support Grant, especially as they relate to optimal means of compliance. Selected cancer centers that are preparing, or have recently completed, core grant submissions will be highlighted.

**Moderator:** Dr. Cheryl L. Willman
University of New Mexico Comprehensive Cancer Center

Dr. Randall F. Holcombe
University of Hawai’i Cancer Center
University of Hawai’i at Manoa

Dr. Eric Fearon
University of Michigan Comprehensive Cancer Center

Dr. Howard Bailey
University of Wisconsin Carbone Cancer Center

4:00 pm  **General Sessions End**

4:00 pm  **CCAF Business Meeting** (closed session)

4:00 – 6:00 pm  **5th Annual AACI Physician Clinical Leadership Initiative Meeting**
Independence Ballroom BCDE, Independence Level

6:00 – 7:30 pm  **Welcome Reception**
Grand Foyer, Declaration Level

Monday, October 16

7:00 am  **General Breakfast**
Independence Ballroom FGHI, Independence Level

7:00 am  **Exhibits Open**  Independence Foyer, Independence Level

8:00 am  **Update on the Network Care Initiative**
Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups. AACI’s Network Care Initiative aims to better define these networks and to develop methods of improving the quality of cancer care administered across individual cancer center networks, with better integration of treatment services, especially those now unique to our centers, into the community. AACI President Dr. Stanton Gerson will provide an update on the initiative, including results of AACI’s survey about the current status of networks.

Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

4:00 pm  **General Sessions End**

4:00 pm  **CCAF Business Meeting** (closed session)

4:00 – 6:00 pm  **5th Annual AACI Physician Clinical Leadership Initiative Meeting**
Independence Ballroom BCDE, Independence Level

6:00 – 7:30 pm  **Welcome Reception**
Grand Foyer, Declaration Level

8:30 am  **Outreach in Community Networks – Challenges and Opportunities**
Without a clear roadmap, managing cancer center networks is a challenging, complex task. Ensuring that the same level of consistent, high quality care delivered at the flagship facility is experienced by patients at satellite locations requires uniform policies and procedures. Panelists will address some of the issues that AACI cancer centers face in operating their networks, such as employment network models, referral patterns, access to clinical trials, use of care paths, and monitoring quality care.

**Moderator:** Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Dr. Karen E. Knudsen
Sidney Kimmel Cancer Center at Thomas Jefferson University

Dr. Gerold Bepler
Barbara Ann Karmanos Cancer Institute
Wayne State University

Dr. Brian J. Bolwell
Cleveland Clinic Taussig Cancer Institute
The Cleveland Clinic Foundation
9:45 am  Distinguished Scientist Award Presentation
         Recent Advances in T Cell Therapy for Cancer Treatment
         Dr. June's talk will revolve around his ongoing work and recent U.S. Food and Drug Administration (FDA) approval of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Trials of this approach have also begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma, and the brain cancer glioblastoma. The implications of the first approval of gene transfer therapy by the U.S. FDA will be discussed.
         Dr. Carl H. June
         Abramson Cancer Center of the University of Pennsylvania

10:45 am  Concurrent Session
         New CCSG Section: Training and Education
         A new component of NCI’s Cancer Center Support Grant (CCSG) application, “Cancer Research Career Enhancement and Related Activities”, highlights efforts to coordinate and enhance existing cancer research education, training, and career development activities. Panelists will address the general structure of the new section, its scope and expectations, and appropriate items to highlight and outcomes to document. They will also provide specific examples of how centers completed the new section in recent CCSG applications.
         Moderator: Mr. David M. Gosky
         UK Markey Cancer Center
         Mr. Alex Zafirovski
         The Robert H. Lurie Comprehensive Cancer Center of Northwestern University
         Ms. Jane Welter
         Mayo Clinic Cancer Center

10:45 am  Concurrent Session
         Immunotherapy: The End of the Beginning?
         Independence Ballroom BCDE, Independence Level
         Growing momentum in the successful implementation of immunotherapeutic strategies has shifted the patient care model, raising immunotherapy's profile as the fourth pillar in the standard of care, joining surgery, chemotherapy and radiotherapy. This panel discussion will highlight various recent technological breakthroughs in areas including the underlying mechanisms of chronic lymphocytic leukemia and immune checkpoint inhibition in the tumor microenvironment.
         Moderator: Dr. Laurie H. Glimcher
         Dana-Farber Cancer Institute
         Harvard Medical School
         Dr. Padmanee Sharma
         University of Texas MD Anderson Cancer Center
         Dr. Juan Cubillos-Ruiz
         Weill Cornell Medical College, Cornell University
         Dr. Catherine J. Wu
         Dana-Farber Cancer Institute
         Harvard Medical School

12:00 pm  AACI Awards Lunch
         Independence Ballroom FGHI, Independence Level
         2017 AACI Distinguished Public Service Award
         The Honorable Roy Blunt (R-MO)
         2017 AACI Distinguished Public Service Award
         The Honorable Bob Casey (D-PA)

1:00 pm  Networking, Dessert and CRI Posters
         Independence Foyer, Independence Level

2:00 pm  Clinical Trial Deployment Within the Community
         Conducting effective cancer clinical trials often requires engagement by both community and academic partners in a myriad of activities spanning protocol design through dissemination of study findings. Such cooperation can increase accrual of underserved and underrepresented populations. Panelists will explore methods of improving clinical trial management, strategic planning and project implementation to boost research participation by underrepresented diverse populations and to improve cancer prevention and control programming.  Continued page 8
### Agenda

**Monday, October 16 continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Exhibits Open</td>
<td>Independence Foyer, Independence Level</td>
</tr>
<tr>
<td>8:00 am</td>
<td>NCI Director’s Report</td>
<td>Lafayette Park/Farragut Square, Independence Level</td>
</tr>
<tr>
<td>7:00 am</td>
<td>General Breakfast</td>
<td>Independence Ballroom FGHI, Independence Level</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Topic Specific Breakfast Roundtable Discussions</td>
<td>Lafayette Park/Farragut Square, Independence Level</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Exports Open</td>
<td>Independence Foyer, Independence Level</td>
</tr>
<tr>
<td>8:00 am</td>
<td>NCI Director’s Report</td>
<td>Lafayette Park/Farragut Square, Independence Level</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Concurrent Session <strong>Precision Medicine Update</strong></td>
<td>Independence Ballroom BCDE, Independence Level</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Practical Advice for a Successful CCSG Submission</td>
<td>Independence Ballroom BCDE, Independence Level</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

**3:30 pm** Concurrent Session

**Precision Medicine Update**
Independence Ballroom BCDE, Independence Level

The impact of recent scientific discoveries related to precision medicine will be the focus of this session, with panelists highlighting their recent work, including resistance to targeted therapy and advances in the areas of prostate and lung cancer and leukemia.

**Moderator:** Dr. Gerold Bepler  
Barbara Ann Karmanos Cancer Institute  
Wayne State University

**Dr. Eric B. Haura**  
Moffitt Cancer Center

**Dr. Nikhil Wagle**  
Dana-Farber Cancer Institute  
Harvard Medical School

**Dr. Jill M. Kolesar**  
UK Markey Cancer Center

**5:00 pm** Sessions End

---

**Tuesday, October 17**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>General Breakfast</td>
<td>Independence Ballroom FGHI, Independence Level</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Topic Specific Breakfast Roundtable Discussions</td>
<td>Lafayette Park/Farragut Square, Independence Level</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Exhibits Open</td>
<td>Independence Foyer, Independence Level</td>
</tr>
<tr>
<td>8:00 am</td>
<td>NCI Director’s Report</td>
<td>Lafayette Park/Farragut Square, Independence Level</td>
</tr>
</tbody>
</table>

**3:30 pm** Concurrent Session

**Precision Medicine Update**
Independence Ballroom BCDE, Independence Level

The impact of recent scientific discoveries related to precision medicine will be the focus of this session, with panelists highlighting their recent work, including resistance to targeted therapy and advances in the areas of prostate and lung cancer and leukemia.

**Moderator:** Dr. Gerold Bepler  
Barbara Ann Karmanos Cancer Institute  
Wayne State University

**Dr. Eric B. Haura**  
Moffitt Cancer Center

**Dr. Nikhil Wagle**  
Dana-Farber Cancer Institute  
Harvard Medical School

**Dr. Jill M. Kolesar**  
UK Markey Cancer Center

---

Program Subject to Change
8:45 am  **Reducing Barriers to Care**

Cancer disparities result from a variety of factors including access to care, lifestyle choices such as smoking or dietary habits, and pervasive social and economic challenges. Resolving such a multi-layered problem requires a multi-level solution. Panelists will discuss a number of approaches that they have implemented to bridge the gap between the causes of cancer and effective patient care.

**Moderator:** Dr. Eduardo Sotomayor  
GW Cancer Center

**Dr. Sanjeev Arora**  
University of New Mexico Comprehensive Cancer Center

**Dr. Vanessa B. Sheppard**  
VCU Massey Cancer Center

**Ms. Dana Dornsife**  
Lazarex Cancer Foundation

**Ms. Mandi Pratt-Chapman**  
GW Cancer Center

9:45 am  **Break**

10:00 am  **Paying for Cancer Care: Will Washington Change the Rules?**

With the change in administration and a single party majority in Congress, cancer centers are adapting to Washington’s new landscape. With the potential repeal and replacement of The Patient Protection and Affordable Care Act (ACA) as well as policy changes that may bear on the cost of oncology drugs, insurance preauthorization, and Medicare and Medicaid reimbursement rates, panelists will discuss how policymakers in Washington are reshaping healthcare.

**Moderator:** Dr. Roy A. Jensen  
The University of Kansas Cancer Center

**Dr. Otis Brawley**  
American Cancer Society

**Dr. Stephen Gruber**  
USC Norris Comprehensive Cancer Center

11:15 am  **Update on the NCI Cancer Centers Program**

**Dr. Henry P. Ciolino**  
National Cancer Institute

12:00 pm  **Adjourn**
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the CME Request for Credit Survey by Tuesday, December 5, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

• NCI’s priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers.
• Models of care across cancer center networks which satisfy efforts to integrate treatment services into the community.
• Implementation of immunotherapeutic strategies in the patient care model.
• Collaborations with community partners in an effort to improve access to care for patients from underserved areas.
• The complexities of implementing precision medicine at cancer centers.
• Approaches to care which bridge the gap between the causes of cancer and effective patient care.
• Changes to healthcare coverage under the new federal administration.

Continuing Medical Education

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call 412-647-6111 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACR’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders, as well as leaders from industry and government agencies and those of cancer research and advocacy organizations, attend the meeting. All attendees have a significant impact on cancer research and patient care. The attendees are medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.
2017 AACI Distinguished Scientist Award

Dr. Carl H. June
Abramson Cancer Center of the University of Pennsylvania

The Association of American Cancer Institutes (AACI) will present the 2017 AACI Distinguished Scientist Award to Carl H. June, MD, on October 16, during the AACI/CCAF Annual Meeting, in Washington, DC.

Dr. June is director of translational research at the Abramson Cancer Center of the University of Pennsylvania, director of the Parker Institute for Cancer Immunotherapy and the Center for Cellular Immunotherapies, and Richard W. Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania.

In 2011, Dr. June's research team published findings which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Early results in that group show that 90 percent of patients respond to the therapy, and more recently, trials of this approach have begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma, and the brain cancer glioblastoma. In 2014, it became the first personalized cellular therapy for the treatment of cancer therapy to receive the U.S. Food and Drug Administration's prestigious Breakthrough Therapy designation.

Dr. June is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland, and post-doctoral training in transplantation biology with Drs. E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle.

The AACI Distinguished Scientist Award acknowledges extraordinary scientific accomplishments and contributions to cancer research. Previous honorees are James P. Allison, Lewis Cantley, Brian Druker, Lee Hartwell, Mary-Claire King, Timothy Ley, Janet Rowley, Stuart Schreiber, Margaret R. Spitz, Bert Vogelstein, Robert Weinberg and Irving Weissman.

2017 AACI Distinguished Public Service Award

The Honorable Roy Blunt (R-MO)
U.S. Senate

Sen. Blunt is chairman of the Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies. Since assuming the chairmanship, he has worked tirelessly to boost federal funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI). Chairman Blunt has displayed bipartisanship as chair of the subcommittee, working with his partner across the aisle, 2015 AACI Public Service Awardee Senator Patty Murray (D-WA), to ensure increases for the NIH over the last two budget cycles.

Chairman Blunt served as a member of the House of Representatives prior to his election to the Senate in 2010 and has been an ally to Siteman Cancer Center in St. Louis, Missouri.


The Honorable Bob Casey (D-PA)
U.S. Senate

First elected to the U.S. Senate in 2006, Sen. Casey is a member of the Senate Committee on Health, Education, Labor, and Pensions (HELP). For the last several years, he has partnered with Republican colleague, 2015 Hill Day Public Service Awardee Senator Richard Burr (R-NC), in writing appropriators, requesting a strong funding commitment for the NIH in the appropriations bill. Sens. Casey and Burr have maintained that a strong investment in the NIH yields scientific advances and improves health outcomes. They warned that any cut to biomedical research funding would cause the country to lose its competitive edge, as well as discourage young researchers from pursuing a career in the field.

Sen. Casey has been a steadfast supporter of AACI's Pennsylvania members: Abramson Cancer Center of the University of Pennsylvania; Fox Chase Cancer Center, Temple Health; Penn State Cancer Institute; Sidney Kimmel Cancer Center at Thomas Jefferson University; The Wistar Institute; and UPMC Hillman Cancer Center.

Sen. Casey has long been an advocate of the Children's Health Insurance Program (CHIP). He was a strong supporter of the Children's Health Insurance Program Reauthorization Act of 2009 and of extending funding for CHIP in 2015.
Keynote Speaker

Stan Collender
MSLGROUP
Stan Collender, a federal budget issues expert and Merkel cell carcinoma survivor, will deliver the keynote on Sunday, October 15. Mr. Collender’s talk will focus in part on the impact of budget cuts to biomedical research and academic cancer centers.

Mr. Collender was one of 26 patients with advanced Merkel cell carcinoma who joined a clinical trial at the Fred Hutchinson Cancer Research Center’s patient-arm, the Seattle Cancer Care Alliance in Seattle, WA. He is also an expert on the U.S. budget, the congressional budget process, federal fiscal and monetary policy, Congress, and Wall Street’s response to Washington tax and spending proposals, and has worked for the House and Senate Budget Committees as well as for three U.S. representatives on the House Budget and Ways and Means Committees.

Mr. Collender is the founder and principal writer of “Capital Gains and Games,” which the Wall Street Journal has called one of the top 25 economic and financial blogs in the U.S. and is now published by Forbes. He previously wrote “Fiscal Fitness,” in Roll Call, the influential Capitol Hill newspaper and “Budget Battles,” in nationaljournal.com. He is the author of “The Guide to the Federal Budget,” one of the most assigned texts on the subject.

In addition to speaking to more than 100 organizations across the U.S. each year, Mr. Collender appears frequently on radio and television news programs and in print. He was appointed by President Clinton to the presidential commission that studied whether the U.S. should have a capital budget, and he is also an adjunct professor of public policy at Georgetown University.

In August, Mr. Collender published editorials in USA Today touting the life-saving value of clinical trials, and in Forbes magazine, arguing against a proposed massive funding cut for the National Cancer Institute (NCI). In the USA Today piece, he spoke to the need for physicians to dedicate their time and effort to clinical trials and the enormous benefit that the trials and their professional involvement brings to patients. The article was published in light of U.S. Senator John McCain’s (R-AZ) battle with primary glioblastoma. In Forbes, Mr. Collender pushed back against a budget proposed by the Trump administration that would reduce NCI funding by $1 billion.

Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Agilent Technologies, iLab Operations Software
iLab Operations Software, a part of the Agilent CrossLab family, is an enterprise web-based management tool designed to support operations for centralized shared research resources. Its functionality includes service request and milestone management, storeroom management, sample processing, equipment reservation management, usage tracking, billing and invoicing, reporting, lab requisitioning, and spend tracking tools. The Agilent team has extensive experience integrating iLab with institutional financial and identity management systems. As part of the full CrossLab capability, more than 1,000 Core facilities and other shared research resources across over 170 organizations in North America, Europe, and the Asia-Pacific region rely on the iLab software to streamline operations.

BTC Network
BTC Network is an owned and fully integrated network of research institutions across the United States. BTC Network has grown to represent 73 clinical research sites across a range of therapeutic indications with the goal of enhancing operations. BTC has experience working with sites having a variety of setups, from private practices to health systems and academic institutions.

Sites that are a part of BTC Network take advantage of a variety of centralized resources, including but not limited to:

- Partnerships with the industry that allow BTC Network sites to get involved in the most competitive studies
- Access to an experienced financial team, that has expertise in everything from budget/contract negotiations and receivable management to coverage analysis and claims review
- Operational support for SOP creation, workflow management, and staffing
- Implementation of a centralized platform that ties the research operation together, including financials, patient recruitment, and business development
Complion
Complion is a flexible, enterprise platform that enables clinical research sites to centralize and manage regulatory and trial documentation across their institution. Complion removes walls between physicians, administrators and staff by intelligently providing secure access to the right document when they need it. Leading academic medical centers and cancer centers around the country use Complion’s Part 11 platform to streamline operations and improve regulatory compliance.

Florence eBinders
With capabilities spanning eRegulatory, eSource, remote monitoring, eSignatures and study dashboards, eBinders helps AACI sites take on more studies with greater compliance. More centers are migrating their teams’ regulatory and source processes to Florence eBinders because it’s the easiest system to use. Built by a team from Microsoft, Emory Healthcare, and Medtronic, eBinders delivers compliance and software quality at scale. eBinders processes over 10,000 new trial documents a month. What’s new this year? Come talk to us about eDOA and NCI dashboards, or try it yourself—get going on an investigator-initiated study for free.

Forte
Forte provides key solutions for cancer centers, academic medical centers and health systems to unleash their research potential through software, consulting services and managed infrastructure.

With a strong belief in community, collaboration and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research.

Forte provides all research professionals complimentary blog articles, eBooks, webinars and more to support continuous learning on industry topics.

Precision Imaging Metrics
Precision Imaging Metrics promotes communication between oncology and radiology teams and enhances timeliness and quality of imaging review and reporting processes. The clinical trial informatics platform was developed by the Tumor Imaging Metrics Core at Dana-Farber/Harvard Cancer Center and is the only software platform that is tailored to the specific workflow needs of site review. The PIM system consists of two integrated components: a web-based workflow and data management application and an image analysis application. To date, the PIM system has been used by seven NCI-Designated Cancer Centers across the country to assess over 100,000 time points for over 2,500 clinical trials. Please visit www.precisionmetrics.org for more information or email support@precisionmetrics.org to schedule a demo.

Society for Immunotherapy of Cancer
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

Velos
Velos is the trusted clinical trial management software company for cancer centers, academic medical centers, hospitals, governments, and industry sponsors worldwide. The integrated Velos clinical research suite includes the Velos eResearch CRMS; Velos EDC; Velos eSample for biospecimen management; Velos eCompliance for IRB and Protocol Review Committees; Velos IDS for Investigational Drug Services; and Velos Volunteer for patient recruitment. The Velos customer base includes 2,000 research sites, 15,000 active clinical trials, 24 CTSA award recipients, 47 cancer centers, 7 of 12 Best Hospitals for Cancer and 11 of 20 Honor Roll Hospitals (source: U.S. News 2017-2018 Best Hospitals Survey). Stafa Cellular Therapy, or StafaCT, is a Velos subsidiary specializing in software for cellular therapy. The comprehensive StafaCT suite supports cell therapy clinical operations; data management and CIBMTR reporting, ISBT bar coding, FACT accreditation, quality, and compliance. For more information on Velos, visit www.velos.com. For more information on StafaCT, visit www.stafa-CT.com.
### Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Member Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arora</td>
<td>Sanjeev</td>
<td>University of New Mexico Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bailey</td>
<td>Howard</td>
<td>University of Wisconsin Carbone Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bepler</td>
<td>Gerold</td>
<td>Barbara Ann Karmanos Cancer Institute, Wayne State University</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Binder</td>
<td>Adam</td>
<td>Albert Einstein Center, Montefiore Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bolwell</td>
<td>Brian</td>
<td>Cleveland Clinic Lajois Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Brabbs</td>
<td>Julie</td>
<td>University of Michigan Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Brawley</td>
<td>Otis</td>
<td>American Cancer Society</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Chapman</td>
<td>Mattie</td>
<td>GW Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Caiola</td>
<td>Henry</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Colender</td>
<td>Stan</td>
<td>MSGROUP</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Connor</td>
<td>Peter</td>
<td>University of Wisconsin Carbone Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Cubitlo-Ruz</td>
<td>Juan</td>
<td>Weill Cornell Medical College</td>
<td>Qataris Therapeutics</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>D'Agostino</td>
<td>Chiara</td>
<td>Beauty Through the Beast</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Donovan</td>
<td>Maryann</td>
<td>UPMC Hillman Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Dorfhole</td>
<td>Daria</td>
<td>Lazarix Cancer Foundation</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Fearon</td>
<td>Eric</td>
<td>University of Michigan Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Ferris</td>
<td>Robert</td>
<td>UPMC Hillman Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Gerson</td>
<td>Stanton</td>
<td>Case Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Glinsky</td>
<td>Laurne</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Bristol-Myers Squibb, Waters Technologies Corp.</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Gosky</td>
<td>David</td>
<td>UK Markey Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Gruber</td>
<td>Stephen</td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>Biogen International, LLC, Myriad Genetics, Fulgent Genetics</td>
<td>A,G,C</td>
<td>Speaker</td>
</tr>
<tr>
<td>Haura</td>
<td>Eric</td>
<td>Moffitt Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Hofacker</td>
<td>Janie</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Hotcombe</td>
<td>Randall</td>
<td>University of Hawaii Cancer Center</td>
<td>Aleric</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Huusser</td>
<td>Matthew</td>
<td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Jensen</td>
<td>Roy</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>Carl</td>
<td>Abramson Cancer Center of the University of Pennsylvania</td>
<td>Novartis</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Knudson</td>
<td>Karen</td>
<td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td>
<td>Novartis, Sanofi</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Kolesar</td>
<td>Jill</td>
<td>UK Markey Cancer Center</td>
<td>Helix Diagnostics</td>
<td>E</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lowy</td>
<td>Doug</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Mann</td>
<td>Randy</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Mayer</td>
<td>Deborah</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>McClelland</td>
<td>Alan</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Mulvey</td>
<td>Therese</td>
<td>Massachusetts General Hospital, Harvard Medical School</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Santana</td>
<td>Victor</td>
<td>Comprehensive Cancer Center St. Jude Children’s Research Hospital</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Sharma</td>
<td>Padmanee</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Sharpless</td>
<td>Norman</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>G1 Therapeutics, Pfizer, HealthSpan Diagnostics, Unity Biotechnology</td>
<td>A,H,S,C,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sheppard</td>
<td>Vanessa</td>
<td>VCU Massey Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Stolomyor</td>
<td>Eduardo</td>
<td>GW Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara Duffy</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Stinwart</td>
<td>Jessica</td>
<td>University of New Mexico Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Wagle</td>
<td>Nikhil</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Foundation Medicine, Novartis, Merck, Puma Biotechnologies, Grail</td>
<td>S,C,G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Welter</td>
<td>Jane</td>
<td>Mayo Clinic Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Willman</td>
<td>Cheryl</td>
<td>University of New Mexico Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Wu</td>
<td>Catterine</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Neon Therapeutics</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Zafar</td>
<td>Yousuf</td>
<td>Duke Cancer Institute</td>
<td>Novartis</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Zafirovski</td>
<td>Alex</td>
<td>The Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
</tbody>
</table>

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers’ Bureau; H, Honoraria; O, Other.
Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- AstraZeneca
- Foundation Medicine
- Gilead
- Huron Consulting Group
- Lilly
- Merck
- Novartis
- Pfizer
- Tyler & Company

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Complion
- Forte Research Systems
- Genentech
- Gilead
- Janssen Research & Development
- Lilly
- Merck
- Pfizer
- Takeda Oncology
- Velos

Support as of October 2, 2017

CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Claimed Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday 10/15/17</td>
<td>1:45 – 2:45 pm</td>
<td>Opening Keynote Speaker</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:00 – 4:00 pm</td>
<td>Impact of the New CCG Guidelines on the Cancer Centers</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:00 – 6:00 pm</td>
<td>5th Annual AACI Physician Clinical Leadership Initiative Meeting</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maximum Approved Credits for 10/15/17</strong></td>
<td><strong>4.0</strong></td>
<td><strong>TOTAL:</strong></td>
</tr>
<tr>
<td>Monday 10/16/17</td>
<td>8:00 – 8:30 am</td>
<td>Update on the Network Care Initiative</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 – 9:30 am</td>
<td>Outreach in Community Networks – Challenges and Opportunities</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:45 – 10:45 am</td>
<td>AACI Distinguished Scientist Presentation</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:45 – 11:45 am</td>
<td>Immunotherapy: The End of the Beginning? (concurrent)</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New CCGS section: Training and Education (concurrent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:00 – 3:15 pm</td>
<td>Clinical Trial Deployment within the Community</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:30 – 5:00 pm</td>
<td>Precision Medicine Update (concurrent)</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCGS Nuts and Bolts (concurrent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maximum Approved Credits for 10/16/17</strong></td>
<td><strong>6.25</strong></td>
<td><strong>TOTAL:</strong></td>
</tr>
<tr>
<td>Tuesday 10/17/17</td>
<td>8:00 – 8:45 am</td>
<td>NCI Director’s Report</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:45 – 9:45 am</td>
<td>Reducing Barriers to Care</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00 – 11:15 am</td>
<td>Paying for Cancer Care: Will Washington Change the Rules?</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:15 – 12:00 pm</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maximum Approved Credits for 10/17/17</strong></td>
<td><strong>3.75</strong></td>
<td><strong>TOTAL:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maximum CME Credits Approved</strong></td>
<td><strong>14.00</strong></td>
<td><strong>TOTAL:</strong></td>
</tr>
</tbody>
</table>